ABN401

Cat. No.: HY-147040

CAS No.: 2242563-15-9

Molecular Formula: $C_{29}H_{34}N_{12}O$

Molecular Weight: 566.66

Target: c-Met/HGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (17.65 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7647 mL	8.8236 mL	17.6473 mL
	5 mM	0.3529 mL	1.7647 mL	3.5295 mL
	10 mM	0.1765 mL	0.8824 mL	1.7647 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1 mg/mL (1.76 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1 mg/mL (1.76 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC_{50} value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer[1].

IC_{50} & Target

IC_{50}: 10 nM (c-MET)[1]

REFERENCES

[1]. Kim J, et al. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers (Basel).

2020;12(6):1575. Published 2020 Jun 15.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA